In addition to being the core factor in thrombosis, thrombin is involved in various inflammatory disease responses, but few studies have examined whether and how it is involved in membrane‐related inflammation. In this study, the thrombin inhibitor dabigatran is used to modify a polyethersulfone dialysis membrane. The modified membrane shows good hydrophilic properties and dialysis performance. It reduces the thrombin level in a targeted manner, thereby significantly inhibiting coagulation factor activation (based on the prothrombin time, international normalized ratio, activated partial thromboplastin time and thrombin time) and reducing the fibrinogen level and platelet adhesion. On thromboelastography, it shows excellent dynamic antithrombotic capacity. The modified membrane inhibited membrane‐related inflammation by inhibiting the production of the inflammatory mediators C‐reactive protein (CRP), interleukin‐6 (IL‐6), and interleukin‐1β (IL‐1β) via the thrombin/complement C5a pathway. Moreover, it is found to be safe in an in vivo study. Thus, the dabigatran‐modified polyethersulfone membrane may reduce dialysis‐related complications through its dual antithrombotic and anti‐inflammatory effects. In addition to participating in coagulation, thrombin activates complement C5a to stimulate inflammatory cells (neutrophils) to produce inflammatory mediators and participate in inflammatory responses. The DMPES membranes inhibit inflammation and thrombin.